{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094542","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-08-12T12:35:13+00:00","discovered_at":"2026-08-12T12:40:00.233934+00:00","generated_at":"2026-08-12T12:40:09.948673+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aprea Q2 2026: net loss $3.6M, cash $41.2M, APR-1051 enrollment accelerating","bullets":["Cash $41.2M at June 30, 2026 vs $14.6M at Dec 31, 2025; runway into Q1 2028.","Net loss $3.6M ($0.07/share) on 53.5M shares vs $3.2M ($0.53/share) on 6.1M shares in Q2 2025.","APR-1051 Phase 1 trial sites expand 3 to 10; enrollment 6-10 patients/month by Q4 2026; next data at Q4 2026 medical meeting.","Plans to advance APR-1051 in USC and Cyclin E-overexpressing PROC; combinations in HPV+ head/neck and colorectal cancer.","$30M private placement closed Q1 2026; ATRN-119 study closed, combinations under discussion."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094542","json":"https://secwatch.observer/filing/0001104659-26-094542.json","markdown":"https://secwatch.observer/filing/0001104659-26-094542.md","text":"https://secwatch.observer/filing/0001104659-26-094542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/0001104659-26-094542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:40:09.948673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}